{"id":51881,"date":"2025-12-23T23:18:05","date_gmt":"2025-12-23T15:18:05","guid":{"rendered":"https:\/\/flcube.com\/?p=51881"},"modified":"2025-12-23T23:18:06","modified_gmt":"2025-12-23T15:18:06","slug":"nmpa-issues-internet-pharma-info-rules-requiring-record-filing-display","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51881","title":{"rendered":"NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display"},"content":{"rendered":"\n

China\u2019s National Medical Products Administration (NMPA)<\/strong> released the “Announcement on the Provisions for the Administration of Record-Filing of Internet Pharmaceutical and Medical Device Information Services,”<\/strong> effective immediately. The regulation mandates that all websites, mobile clients, and applications providing pharmaceutical or medical device information services in China must prominently display their record-filing certificate numbers<\/strong> and prohibits publishing information on narcotic drugs, psychotropic drugs, medical toxic drugs, radioactive drugs, drug rehabilitation medications, and hospital-made preparations<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Issuance Date<\/strong><\/td>22\u202fDec\u202f2025<\/td><\/tr>
Effective Date<\/strong><\/td>Date of publication (immediate)<\/td><\/tr>
Agency<\/strong><\/td>National Medical Products Administration (NMPA)<\/td><\/tr>
Document<\/strong><\/td>Provisions for Administration of Record-Filing of Internet Pharmaceutical and Medical Device Information Services<\/td><\/tr>
Scope<\/strong><\/td>All internet platforms providing pharma\/medical device info services within China<\/td><\/tr>
Enforcement Body<\/strong><\/td>NMPA responsible for nationwide guidance and supervision<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Key Provisions<\/h2>\n\n\n\n
Requirement<\/th>Details<\/th><\/tr><\/thead>
Record-Filing Display<\/strong><\/td>Websites\/clients\/apps must continuously and prominently display certificate number on homepage\/main interface<\/td><\/tr>
Prohibited Content<\/strong><\/td>Narcotic drugs, psychotropic drugs, medical toxic drugs, radioactive drugs, drug rehabilitation medications, hospital-made preparations (strictly banned)<\/td><\/tr>
Compliance Timeline<\/strong><\/td>Immediate enforcement; platforms must update within 30 days<\/td><\/tr>
Penalty Structure<\/strong><\/td>Non-compliance may result in service suspension, fines up to \u00a5500,000, or criminal referral<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact<\/h2>\n\n\n\n
Stakeholder<\/th>Impact<\/th><\/tr><\/thead>
Internet Platforms<\/strong><\/td>~2,000+ health info sites require immediate compliance updates; estimated \u00a550\u201180 million<\/strong> in aggregate compliance costs<\/td><\/tr>
Digital Health Startups<\/strong><\/td>Increased regulatory barrier to entry; existing platforms with robust compliance gain competitive advantage<\/td><\/tr>
Pharma Advertisers<\/strong><\/td>Restricted from promoting controlled substances online; forces shift to approved drug information only<\/td><\/tr>
Consumers<\/strong><\/td>Enhanced safety and information accuracy; reduced exposure to illicit drug promotions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n